Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 76420-236

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 76420-236). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Duloxetine 30 mg delayed-release pellets in capsule form, labeled for oral use. The capsule features a two-tone design with a purple and pink color scheme and is marked with identification codes. The label indicates the product is manufactured by Asclemed USA, Inc.*

FDA Label Image

Figure9 (Image 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, showing data for Duloxetine Delayed-Release 60 mg once daily and placebo groups. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percentage of patients improved, with results indicating higher improvement percentages for the Duloxetine group across most pain improvement levels.*

FDA Label Image

Figure10 (Image 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The graph includes two plots: placebo indicated by crosses with a dotted line, and Duloxetine delayed-release 60/120 mg once daily indicated by diamonds with a solid line. The Duloxetine group consistently shows a higher percentage of patients improved across the range of pain improvement percentages.*

FDA Label Image

1 (Image 12)

Duloxetine 30 mg delayed release pellets in capsule form, labeled for oral use, displayed in a clear plastic blister pack. The packaging shows individual capsules with a distinctive two-toned color, typically associated with Duloxetine capsules, manufactured by Asclemed USA, Inc.*

FDA Label Image

Label 30 mg (Image 13)

This image shows multiple packaging labels for Duloxetine DR Capsules, USP 30mg, delayed release pellets in capsule form. The labels indicate packaging by Enovachem Pharmaceuticals and releaser information, with quantities of 30, 60, and 90 capsules. Each label features NDC 76420-236-30 and includes batch and manufacturing details, caution statements, barcodes, and QR codes. The labels are for oral prescription use and manufactured for Teva Pharmaceuticals.*

FDA Label Image

1 (Image 2)

Chemical structure of duloxetine hydrochloride, showing the molecular arrangement with a thiophene ring, naphthalene moiety, and amine hydrochloride group.*

FDA Label Image

Figure1 (Image 3)

Kaplan-Meier curve showing the proportion of patients with relapse over time in days from randomization, comparing Duloxetine 30 mg delayed-release capsules to placebo. The graph depicts relapse rates with Duloxetine lower than placebo throughout the observation period up to 200 days.*

FDA Label Image

Figure2 (Image 4)

Kaplan-Meier curve chart showing the proportion of patients with relapse over time (in days) from randomization. The graph compares relapse rates between Duloxetine delayed-release capsules and placebo treatments, illustrating lower relapse proportions for Duloxetine across the observed period.*

FDA Label Image

Figure3 (Image 5)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing trends of patient improvement across increasing pain relief percentages.*

FDA Label Image

Figure4 (Image 6)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, showing patient improvement trends across varying pain improvement percentages.*

FDA Label Image

Figure5 (Image 7)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating differences in pain improvement response.*

FDA Label Image

Figure6 (Image 8)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Duloxetine (DUL) at doses of 120 mg, 60 mg, 20 mg once daily, and a placebo group. The y-axis represents the percentage of patients improved, ranging from 0 to 100, and the x-axis shows percent improvement in pain from baseline, categorized in increments from >0 to 100. The Duloxetine groups show higher percentages of patient improvement compared to the placebo group across the pain improvement percentages.*

FDA Label Image

Figure8 (Image 9)

A line chart depicting the percentage of patients improved versus the percent improvement in pain from baseline (BOCF). Two lines compare Placebo and Duloxetine Delayed-Release 60/120 mg once daily, showing greater patient improvement percentages across increasing pain improvement thresholds for Duloxetine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.